The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TBPH | +93.11% | -3.44% | -0.7% | -18% |
| S&P | +16.49% | +84.25% | +12.99% | +264% |
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
The company is making excellent progress on all its strategic goals.
The biotech is not enjoying a winning streak with its pipeline drugs.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $19.99M | 18.5% |
| Gross Profit | $18.58M | 21.4% |
| Gross Margin | 92.96% | 2.2% |
| Market Cap | $735.28M | 86.5% |
| Market Cap / Employee | $7.58M | 0.0% |
| Employees | 97 | -2.0% |
| Net Income | $3.62M | 128.5% |
| EBITDA | -$5.05M | 34.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $174.77M | 647.6% |
| Accounts Receivable | $18.27M | 8.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $33.68M | -17.4% |
| Short Term Debt | $10.91M | 160.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 7.61% | 20.4% |
| Return On Invested Capital | -46.45% | 12.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.51M | -24.9% |
| Operating Free Cash Flow | -$6.51M | -25.3% |
| Metric | Q2 2025 | Q3 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 47.16 | 25.96 | - | ||
| Price to Book | 2.49 | 2.52 | 3.32 | 3.27 | 60.63% |
| Price to Sales | 7.21 | 6.80 | 7.25 | 9.43 | 50.84% |
| Price to Tangible Book Value | 2.49 | 2.52 | 3.32 | 3.27 | 60.63% |
| Price to Free Cash Flow TTM | 13.75 | 2.29 | 3.11 | - | |
| Enterprise Value to EBITDA | -54.30 | -25.53 | -194.16 | -93.66 | 107.17% |
| Free Cash Flow Yield | 7.3% | 43.7% | 32.1% | - | |
| Return on Equity | -29.0% | -31.5% | 6.2% | 14.0% | -161.31% |
| Total Debt | $49.82M | $79.13M | $46.46M | $44.60M | -0.86% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
